Phase 2 Psoriasis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who are willing and able to sign a consent form before any study activities begin, and who are able to follow all study procedures
• People who have been diagnosed with plaque psoriasis for at least 6 months, whose condition is currently suitable for treatment with creams or ointments applied to the skin, and whose psoriasis meets specific severity and affected skin area measurements at the screening and baseline visits (the affected area must be between 3% and 15% of the body, not counting the head, and the investigator must rate the severity at a certain level — confirm with trial site)
• People who agree to avoid prolonged sun exposure (such as sunbathing) during the study, and who agree not to use tanning beds or LED light devices

Who may not be able to join:

• People whose psoriasis is mainly a type other than plaque psoriasis — for example, psoriatic arthritis, pustular, erythrodermic, guttate, or psoriasis affecting the palms, soles, scalp, or nails — or whose condition requires treatment beyond skin-applied products
• People with a serious medical or psychiatric condition, or significant abnormal lab results, that the investigator determines would make study participation unsafe or unsuitable
• People with known or suspected severe kidney or liver problems
• People with a history of severe depression or thoughts or actions related to suicide within the 2 years before screening
• People who test positive at screening for HIV, Hepatitis B, or Hepatitis C
• People with active tuberculosis (TB), or latent TB that has not been treated according to local medical guidelines
• People with a current or past history of inflammatory bowel disease (such as ulcerative colitis or Crohn's disease), or who show signs of this condition at screening that the investigator considers to pose an unacceptable risk
• People with a history of a serious allergic reaction (such as anaphylaxis) to a type of medication known as IL-17 antibodies, or to any human or humanised biological medicines
• People with a history of cancer, unless they have been considered fully treated with no signs of return for at least 3 years before the study begins
• People with a history of long-term alcohol or drug misuse within 6 months before the study begins, as determined by the investigator
• People who have previously received the study drug ZL-1102
• People who have received a live vaccine within 6 weeks before the first dose of the study drug
• People who are pregnant, planning to become pregnant during the study, or who are currently breastfeeding

Important: Always verify eligibility with the trial site directly before applying.